{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:14:08Z","timestamp":1793783648830,"version":"4.6.1"},"reference-count":227,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ymgme.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T17:48:06Z","timestamp":1626889686000},"page":"117-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing"],"prefix":"10.1016","volume":"134","author":[{"given":"Jakob M.","family":"Domm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.07.006_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0025","doi-asserted-by":"crossref","first-page":"100530","DOI":"10.1016\/j.ymgmr.2019.100530","article-title":"Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients","volume":"21","author":"Kritzer","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0030","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/DDDT.S249433","article-title":"Analysis of renal and cardiac outcomes in male participants in the fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age","volume":"14","author":"Parini","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"Elliott","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0055","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0080","first-page":"1","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","author":"Ortiz","year":"2020","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0085","series-title":"Cardio-Renal Outcomes with Long-Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey (FOS) Analysis on Behalf of the FOS Study Group","author":"Ramaswami","year":"2019"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: outcome From a Prospective Observational Multicenter Study (FAMOUS)","author":"Lenders","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0095","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00019053-200725030-00003","article-title":"Enzyme replacement therapy in orphan and ultra-orphan diseases","volume":"25","author":"Moore","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0115","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0120","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0125","series-title":"Replagal - PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION","author":"Shire Human Genetic Therapies, I","year":"2017"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0130","series-title":"Fabrazyme - PRODUCT MONOGRAPH Agalsidase Beta (Recombinant Human \u03b1-Galactosidase a) Enzyme Replacement Therapy","author":"Sanofi Genzyme","year":"2017"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-galactosidase a replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0140","doi-asserted-by":"crossref","DOI":"10.3171\/FOC\/2008\/24\/3-4\/E11","article-title":"Central nervous system therapy for lysosomal storage disorders","volume":"24","author":"Enns","year":"2008","journal-title":"Neurosurg. Focus."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector iterations and pre-clinical scale-up\/toxicity testing: targeting mobilized CD34 + cells for correction of Fabry disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12033-007-9008-5","article-title":"Naked plasmid DNA-based \u03b1-galactosidase a gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice","volume":"38","author":"Nakamura","year":"2008","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0160","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0165","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0170","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5358272","article-title":"Posttranslational modifications and the immunogenicity of biotherapeutics","volume":"2016","author":"Jefferis","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0180","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1089\/10430349950017293","article-title":"Circulating \u03b1-galactosidase a derived from transduced bone marrow cells: relevance for corrective gene transfer for fabry disease","volume":"10","author":"Takenaka","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0185","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1073\/pnas.93.15.7917","article-title":"Correction in trans for Fabry disease: expression, secretion, and uptake of a-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector","volume":"93","author":"Medin","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0190","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer","volume":"10","author":"Ziegler","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0195","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/10430340252939041","article-title":"Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease","volume":"13","author":"Ziegler","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0200","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1006\/mthe.2002.0605","article-title":"Adenovirus-transduced lung as a portal for delivering \u03b1-galactosidase a into systemic circulation for Fabry disease","volume":"5","author":"Li","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/hum.2010.069","article-title":"\u03b1-Galactosidase a expressed in the salivary glands partially corrects organ biochemical deficits in the fabry mouse through endocrine trafficking","volume":"22","author":"Passineau","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0210","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","article-title":"Intravascular adenoviral agents in cancer patients: lessons from clinical trials","volume":"9","author":"Reid","year":"2002","journal-title":"Cancer Gene Ther."},{"issue":"1612","key":"10.1016\/j.ymgme.2021.07.006_bb0215","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"Can. Med. Assoc."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0220","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.187","article-title":"Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic levels of enzyme activity and effective substrate reduction in mouse model of Fabry disease","volume":"126","author":"Huston","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0225","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ymgme.2018.12.196","article-title":"Liver-directed gene therapy corrects Fabry disease in mice","volume":"126","author":"Jeyakumar","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of Fabry disease results in Supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of \u03b1-galactosidase a and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0240","series-title":"Nephron 6th Updat. Fabry Dis","article-title":"Investigation of a Novel adeno-associated viral vector gene therapy (FLT190) in patients with Fabry Disease \u2013 design of the phase 1\/2 study","volume":"Vol. GT-03","author":"Patel","year":"2019"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0245","series-title":"Nephron 6th Updat. Fabry Dis","article-title":"A novel cardiotropic AAV variant 4D-C102 demonstrates: superior gene delivery and reduced immunogenicity in cardiac tissues versus wildtype AAV in non-human primates, and results in functional GLA in cardiomyocytes and Fabry fibroblasts","volume":"Vol. GT-04","author":"Whittlesey","year":"2019"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0250","series-title":"Am. Soc. gene cell Ther. 2020 Conf","article-title":"In vitro fabry disease correction in patient iPSC-derived cardiomyocytes and endothelial cells using an evolved and optimized AAV gene therapeutic (4D-310)","author":"Schmitt","year":"2020"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0255","series-title":"Am. Soc. gene cell Ther. 2020 Conf","article-title":"A highly-evolved novel AAV gene therapy directly addresses fabry disease pathology in vivo by cell autonomous expression in the heart and other target organs","author":"Whittlesey","year":"2020"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz748.0278","article-title":"P1516 novel cardiotropic AAV variant C102 vectors show superior gene delivery & reduced immunogenicity in non-human primates, transduction of human cardiomyocytes, & correction of Fabry disease phenotype","volume":"40","author":"Kotterman","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0265","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0270","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0275","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1128\/JVI.72.12.9795-9805.1998","article-title":"Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure","volume":"72","author":"Halbert","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0280","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Rivi\u00e8re","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0285","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.ymgme.2018.12.248","article-title":"FACTs Fabry gene therapy clinical trial: two-year data","volume":"126","author":"Medin","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0290","series-title":"Am. Soc. gene cell Ther. 2020 Conf.","article-title":"529. Gb3 substrate in endothelial cells of renal peritubular capillaries was reduced in a previously untreated classic Fabry male patient treated with AVR-RD-01 investigational lentiviral gene therapy","author":"Volck","year":"2020"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0295","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0300","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0305","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.stem.2016.04.016","article-title":"In vivo tracking of human hematopoiesis reveals patterns of clonal dynamics during early and steady-state reconstitution phases","volume":"19","author":"Biasco","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0310","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0315","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0320","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0325","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0330","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.261.261","article-title":"Lentiviral hematopoietic stem cell gene therapy for older patients with X-linked severe combined immunodeficiency","volume":"126","author":"De Ravin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0345","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0350","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0355","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0360","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u00df-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0365","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-99-111160","article-title":"Advances in the gene therapy of patients with Fanconi Anemia","volume":"132","author":"Bueren","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0370","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/hum.2018.124","article-title":"Advances in gene therapy for Fanconi Anemia","volume":"29","author":"R\u00edo","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0375","article-title":"Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for Krabbe Disease","author":"Li","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0380","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Therapy - Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0385","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/sj.gt.3302123","article-title":"Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies","volume":"10","author":"Huttner","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0390","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.omtm.2018.04.005","article-title":"A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice","volume":"9","author":"van Lieshout","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0395","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0400","article-title":"Cellular immune responses to vector in a gene therapy trial for hemophilia B using an AAV8 self-complementary factor IX vector","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0405","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0410","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/gt.2010.167","article-title":"Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production","volume":"18","author":"Halbert","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0415","year":"2021","journal-title":"Bus. Wire"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0301-472X(99)00050-8","article-title":"Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem\/progenitor and stromal cells derived from patients with fabry disease","volume":"27","author":"Takenaka","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0425","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1073\/pnas.120177997","article-title":"Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells","volume":"97","author":"Takenaka","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0430","doi-asserted-by":"crossref","first-page":"16909","DOI":"10.1073\/pnas.0407572101","article-title":"Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors","volume":"101","author":"Yoshimitsu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0435","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.gt.3302839","article-title":"Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem\/progenitor cells","volume":"14","author":"Yoshimitsu","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0440","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.mt.6300075","article-title":"Multiple reduced-intensity conditioning regimens facilitate correction of fabry mice after transplantation of transduced cells","volume":"15","author":"Liang","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0445","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/mt.2012.64","article-title":"Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD\/SCID\/Fabry mice","volume":"20","author":"Pacienza","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0450","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4155\/bio-2016-0116","article-title":"Relative distribution of Gb3 isoforms\/analogs in NOD\/SCID\/Fabry mice tissues determined by tandem mass spectrometry","volume":"8","author":"Proven\u00e7al","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0455","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1034\/j.1600-0676.2002.01702.x","article-title":"Cell proliferation and renewal of normal hepatocytes and bile duct cells in adult mouse liver","volume":"22","author":"Magami","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0460","first-page":"1","article-title":"Hemophilia a ameliorated in mice by CRISPR-based in vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bbrc.2018.01.169","article-title":"Nephron segment-specific gene expression using AAV vectors HHS Public Access","volume":"497","author":"Asico","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0470","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/JVI.72.1.180-190.1998","article-title":"Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB","volume":"72","author":"L\u00f6ser","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0475","doi-asserted-by":"crossref","first-page":"18644","DOI":"10.1073\/pnas.0509315102","article-title":"Development of functional human embryonic stem cell-derived neurons in mouse brain","volume":"102","author":"Muotri","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0480","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0485","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/scd.2006.0057","article-title":"Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner","volume":"16","author":"Xia","year":"2007","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0490","first-page":"1","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","author":"Nowak","year":"2021","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0495","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0500","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0505","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0845-z","article-title":"Acid ceramidase deficiency: Farber disease and SMA-PME","volume":"13","author":"Yu","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0515","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physiolgenomics.00052.2019","article-title":"Gene therapy research for kidney diseases","volume":"51","author":"Davis","year":"2019","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0520","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0525","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0530","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0535","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic administration of AAV8-\u03b1-galactosidase a induces humoral tolerance in nonhuman primates despite low hepatic expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0545","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2018-99-118050","article-title":"A single intravenous infusion of FLT180a results in factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with Haemophilia B","volume":"132","author":"Chowdary","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0550","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1096\/fj.14-269092","article-title":"Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates","volume":"29","author":"Mattar","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0555","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood\u2013brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0560","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0565","article-title":"Deep search: next-gen strategies for accelerating AAV capsid engineering","volume":"2018","author":"Kelsic","year":"2018","journal-title":"ASGCT"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0575","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0580","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0585","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0590","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1016\/j.vaccine.2016.10.053","article-title":"Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques","volume":"34","author":"Greig","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0595","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0600","series-title":"Zolgensma Full Prescribing Information","author":"FDA","year":"2019"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000931","article-title":"RNA-Based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma","volume":"2","author":"DiGiusto","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0610","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0615","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.ymgme.2021.07.006_bb0620","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood.V96.10.3385.h8003385_3385_3391","article-title":"Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to Moloney murine leukemia virus-based vectors","volume":"96","author":"Barrette","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0625","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ni.3341","article-title":"The development and maintenance of resident macrophages","volume":"17","author":"Perdiguero","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0630","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/096368979500400409","article-title":"Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases","volume":"4","author":"Krivit","year":"1995","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0635","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic stem cell gene therapy for storage disease: current and new indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0640","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/bloodadvances.2017007773","article-title":"Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent","volume":"1","author":"L\u00e9vy","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0645","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2003-06-1770","article-title":"Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD\/SCID model","volume":"103","author":"Ahmed","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0650","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1742-4690-3-94","article-title":"Lung cancer induced in mice by the envelope protein of jaagsiekte sheep retrovirus (JSRV) closely resembles lung cancer in sheep infected with JSRV","volume":"3","author":"Wootton","year":"2006","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0655","first-page":"1","article-title":"The stability of envelope-pseudotyped lentiviral vectors","author":"Dautzenberg","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0660","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1963","article-title":"Current status on the development of pseudoviruses for enveloped viruses","volume":"28","author":"Li","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0665","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0670","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0675","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0680","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0685","first-page":"37","article-title":"Paediatric Fabry disease","volume":"5","author":"Ellaway","year":"2016","journal-title":"Transl. Pediatr."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0690","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0695","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0700","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504","article-title":"Globotriaosylsphingosine accumulation and not alpha-galactosidase-a deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0710","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2011.06.007","article-title":"Higher apoptotic state in Fabry disease peripheral blood mononuclear cells","volume":"104","author":"De Francesco","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0720","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of Globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0730","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00415-005-0020-z","article-title":"Diffuse structural and metabolic brain changes in Fabry disease","volume":"253","author":"Marino","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0735","series-title":"Bone Marrow Transplantation in Patients Aged","volume":"Vol. 67","author":"Klingemann","year":"1986"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0740","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00000658-200109000-00004","article-title":"One hundred nine living donor liver transplants in adults and children: A single-center experience","volume":"234","author":"Miller","year":"2001","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0745","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156652308786848021","article-title":"Mechanisms governing lentivirus integration site selection","volume":"8","author":"Ciuffi","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0750","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/v2010111","article-title":"Retroviral integration site selection","volume":"2","author":"Desfarges","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0755","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/mt.2009.16","article-title":"Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells","volume":"17","author":"Wang","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0760","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0765","article-title":"Overview of the HIV-1 lentiviral vector system","volume":"16","author":"Ramezani","year":"2002","journal-title":"Curr. Protoc. Mol. Biol"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031081","article-title":"Acute myeloid leukemia in patients living with HIV infection: several questions, fewer answers","volume":"21","author":"Forghieri","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0775","author":"Bluebirdbio"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0780","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0785","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0790","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-018-08224-4","article-title":"Engineering of CRISPR-Cas12b for human genome editing","volume":"10","author":"Strecker","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0795","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0800","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0805","article-title":"Transposon-encoded CRISPR\u2013Cas systems direct RNA-guided DNA integration","volume":"1","author":"Klompe","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0810","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aax9181","article-title":"RNA-guided DNA insertion with CRISPR-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0815","first-page":"9758","article-title":"A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells","volume":"44","author":"Chaikind","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0820","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0825","first-page":"1","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0830","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41586-019-0908-x","article-title":"CasX enzymes comprise a distinct family of RNA-guided genome editors","volume":"566","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0835","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aav7271","article-title":"Functionally diverse type V CRISPR-Cas systems","volume":"363","author":"Yan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0840","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","article-title":"Discovery and functional characterization of diverse class 2 CRISPR-Cas systems","volume":"60","author":"Shmakov","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0845","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.aav4294","article-title":"Programmed DNA destruction by miniature CRISPR-Cas14 enzymes","volume":"362","author":"Harrington","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0850","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0855","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0860","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.2673","article-title":"High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity","volume":"31","author":"Pattanayak","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0865","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nbt.3127","article-title":"Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0870","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0875","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nbt.3101","article-title":"Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases","volume":"33","author":"Frock","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0880","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1093\/nar\/gkt714","article-title":"CRISPR\/Cas9 systems targeting \u03b2-globin and CCR5 genes have substantial off-target activity","volume":"41","author":"Cradick","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0885","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2013.04.015","article-title":"DNA repair mechanisms in dividing and non-dividing cells","author":"Iyama","year":"2013","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0895","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0900","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"Mechanism of double-Strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0905","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0910","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s13238-017-0475-6","article-title":"Correction of \u03b2-thalassemia mutant by base editor in human embryos","volume":"8","author":"Liang","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0915","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s13238-017-0458-7","article-title":"Highly efficient and precise base editing in discarded human tripronuclear embryos","volume":"8","author":"Li","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050511","article-title":"Efficient generation and correction of mutations in human iPS cells utilizing mRNAs of CRISPR base editors and prime editors","volume":"11","author":"S\u00fcr\u00fcn","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Efficient generation of mouse models with the prime editing system","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Disc."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0930","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0935","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1745-6150-1-7","article-title":"A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action","volume":"1","author":"Makarova","year":"2006","journal-title":"Biol. Direct"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0940","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0945","doi-asserted-by":"crossref","DOI":"10.21775\/cimb.028.047","article-title":"CRISPR-based genome editing","author":"Ahmad","year":"2018","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0950","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0955","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0960","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nprot.2017.143","article-title":"CRISPR\/Cas9 genome editing in human hematopoietic stem cells","volume":"13","author":"Bak","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0965","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0970","article-title":"CRISPR\/Cas9-engineered transgenesis of hematopoietic stem cells via NHEJ-mediated targeted integration retains engraftment potential","volume":"2019","author":"Uenishi","year":"2019","journal-title":"ASGCT"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0975","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0980","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0985","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nmeth.3075","article-title":"Adenoviral vector DNA for accurate genome editing with engineered nucleases","volume":"11","author":"Holkers","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymgme.2021.07.006_bb0990","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/nar\/gku749","article-title":"Multiplex CRISPR\/Cas9-based genome engineering from a single lentiviral vector","volume":"42","author":"Kabadi","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb0995","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1000","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cell.2015.08.007","article-title":"Crystal structure of Staphylococcus aureus Cas9","volume":"162","author":"Nishimasu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1005","series-title":"WORLDSymposiumTM Lysosomal Dis. Netw. Meet. 2017","article-title":"Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model results in continuous supra-physiological enzyme activity and effective substrate reduction \u2013 abstract #151","author":"Huston","year":"2017"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1010","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.s043","article-title":"AB043. Correction of the GLA IVS4+919 G>A mutation with CRISPR\/Cas9 deletion strategy in fibroblasts of Fabry disease","volume":"5","author":"Chang","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1015","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I","volume":"408757","author":"Gomez-Ospina","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00439-017-1779-6","article-title":"The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies","volume":"136","author":"Stenson","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/jmg.28.4.232","article-title":"Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte \u03b1-galactosidase activity and an NcoI polymorphism detected by an \u03b1-galactosidase cDNA clone","volume":"28","author":"Kirkilionis","year":"1991","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1030","doi-asserted-by":"crossref","first-page":"35495","DOI":"10.1038\/srep35495","article-title":"High-efficiency transduction of primary human hematopoietic stem\/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing","volume":"6","author":"Ling","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1035","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1038\/s41467-019-10735-7","article-title":"CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites","volume":"10","author":"Jayavaradhan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1040","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051318","article-title":"Improving precise CRISPR genome editing by small molecules: is there a magic potion?","volume":"9","author":"Bischoff","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise gene Editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9336","article-title":"Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells","volume":"8","author":"DeWitt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1055","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1060","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2015-09-672337","article-title":"Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates","volume":"127","author":"Peterson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1065","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Therapy Nucleic Acids"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1070","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nmeth.2812","article-title":"E-CRISP: fast CRISPR target site identification","volume":"11","author":"Heigwer","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR\u2013Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1085","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrmicro.2017.120","article-title":"Anti-CRISPR: discovery, mechanism and function","volume":"16","author":"Pawluk","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1701620","article-title":"Disabling Cas9 by an anti-CRISPR DNA mimic","volume":"3","author":"Shin","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-018-0500-9","article-title":"In vivo CRISPR editing with no detectable genome-wide off-target mutations","volume":"561","author":"Akcakaya","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2021.07.006_bb1130","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41596-020-0309-5","article-title":"CRISPR off-target detection with DISCOVER-seq","volume":"15","author":"Wienert","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2021.07.006_bb1140","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"}],"updated-by":[{"DOI":"10.1016\/j.ymgme.2023.107541","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000}}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221007575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221007575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:02:10Z","timestamp":1725465730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221007575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":227,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1096719221007575"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.07.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}